The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor
Acta Ophthalmologica May 23, 2019
Ceklic L, et al. - Patients with diabetic macular oedema (DME) under continuous anti-vascular endothelial growth factor (VEGF) therapy were examined for the prevalence and impact of ganglion cell layer cysts (GCLC). Researchers determined the impact of GCLC cysts among a total of 110 eyes of 110 DME patients (mean age 64 ± 10 years) via analyzing the retrospectively collected data regarding their clinical findings and spectral domain optical coherence devices of baseline visits and follow-up after 12–24 and 36 months of DME patients under continuous anti-VEGF therapy. Outcomes revealed 68 ± 23.4 μm less central retinal thickness (CRT) decrease in eyes with GCLC than eyes lacking GCLC. GCLC remained a statistically significant factor for the outcome parameter CRT, but missed statistical significance for best-corrected visual acuity, in the linear mixed effect models including external limiting membrane disruption, disintegration of inner retinal layer and epiretinal membrane.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins